According to a FMCG Gurus survey, published in January 2023, 7 in 10 consumers who have heard of blue light are concerned about its negative effects on their eye health. Furthermore, the same research illustrates that over half of North American consumers claim that they will try to improve their eyesight over the next 12 months and a third of them is adapting proactive approaches to prevent eyesight issues before the problems arise.
Consequently, the eye health dietary supplement category is growing. Euromonitor shows it grew at a 6,4% CAGR in the past 5 years – above the average dietary supplement rate of 5,1% – and was the 5th fastest growing category in 2022 with 4,7% y-o-y growth. However, it is still among the smaller categories in dietary supplements. It is still quite niche but developing quickly. The frequency of launches is increasing steeply. According to Mintel, the share of new supplement launches with eye health claims saw a significant jump in 2022 and reached a record high of 5,6%. The difference is that traditionally mainly specialized companies in eye care were launching eye health supplements (e.g., Bausch+Lomb or OmniVision), however, now this has expanded to companies that cover the entire spectrum (e.g., Blackmores or Nature’s Bounty). There are also some movements in the pharma world – for example, in April 2022, a French-based company Urgo Healthcare acquired FB Vision, whose portfolio includes several premium eye health supplements.